JP Morgan Chase
UBX

JP Morgan Chase’s Unity Biotechnology UBX Stock Holding History

JP Morgan Chase’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32
Closed -$33 – 7654
2025
Q1 		$33 Sell
32
-234
-88% -$423 ﹤0.01% 7050
2024
Q4 		$260 Sell
266
-6
-2% -$7 ﹤0.01% 6877
2024
Q3 		$400 Sell
272
-511
-65% -$750 ﹤0.01% 6821
2024
Q2 		$1.06K Buy
783
+512
+189% +$778 ﹤0.01% 6609
2024
Q1 		$444 Buy
271
+14
+5% +$24 ﹤0.01% 6735
2023
Q4 		$496 Buy
257
+6
+2% +$11 ﹤0.01% 6925
2023
Q3 		$602 Sell
251
-552
-69% -$1.46K ﹤0.01% 6699
2023
Q2 		$2.05K Buy
+803
New +$2.12K ﹤0.01% 6332
2022
Q4 		– Sell
-7
Closed – – 7015
2022
Q3 		$0 Buy
+7
New +$44 ﹤0.01% 6868
2022
Q2 		– Hold
0
– – – 6903
2022
Q1 		– Hold
0
– – – 7042
2021
Q4 		– Sell
-8,582
Closed -$188K – 6972
2021
Q3 		$258K Sell
8,582
-7,750
-47% -$273K ﹤0.01% 5103
2021
Q2 		$758K Buy
16,332
+4,026
+33% +$194K ﹤0.01% 4464
2021
Q1 		$739K Buy
12,306
+1,933
+19% +$132K ﹤0.01% 4432
2020
Q4 		$543K Buy
10,373
+9,074
+699% +$438K ﹤0.01% 4318
2020
Q3 		$45K Sell
1,299
-7,171
-85% -$454K ﹤0.01% 4968
2020
Q2 		$735K Buy
8,470
+7,557
+828% +$560K ﹤0.01% 3678
2020
Q1 		$53K Sell
913
-181
-17% -$11.4K ﹤0.01% 4708
2019
Q4 		$79K Buy
1,094
+56
+5% +$3.95K ﹤0.01% 4975
2019
Q3 		$63K Buy
1,038
+212
+26% +$15K ﹤0.01% 5074
2019
Q2 		$69K Buy
826
+126
+18% +$10.7K ﹤0.01% 5054
2019
Q1 		$57K Sell
700
-28
-4% -$3.17K ﹤0.01% 5080
2018
Q4 		$118K Buy
728
+519
+248% +$68.9K ﹤0.01% 4784
2018
Q3 		$34K Buy
209
+106
+103% +$17.5K ﹤0.01% 5320
2018
Q2 		$15K Buy
+103
New +$15.1K ﹤0.01% 5336

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's UBX Position: Q2 2025 in Review

JP Morgan Chase sold out of Unity Biotechnology (UBX) in Q2 2025, closing a stake of 32 shares — an estimated $33 sold.

JP Morgan Chase first reported a position in UBX in Q2 2018 and held it in 23 quarters. The position peaked at $758K in Q2 2021. 35 funds tracked by Wall St. Rank hold UBX as of Q2 2025.

  • JP Morgan Chase reported no remaining Unity Biotechnology position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 32 Unity Biotechnology shares in Q2 2025, an estimated $33.
  • JP Morgan Chase first reported a position in Unity Biotechnology in Q2 2018 and held it in 23 quarters.
  • JP Morgan Chase's Unity Biotechnology position peaked at $758K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.